Japan Picks 24 Medical Studies For New Rule-Relaxation Program
This article was originally published in PharmAsia News
Executive Summary
Japanese authorities have decided to relax some of the nation's regulations for 24 medical research projects on stem cells and medical equipment. The easing also is to be extended for the drug approval process and some regulations in associated fields. The 24 projects identified are among five types, including induced pluripotent stem cells and innovative equipment, regenerative medicine and cancer vaccines. One of the iPS studies on the list is a joint effort by Astellas Pharma, Takeda Pharmaceutical and the University of Kyoto. Previously, the government's rule-relaxation efforts were applied by geographical zones instead of specific projects. (Click here for more - a subscription may be required